Engineering imaging probes and molecular machines for nanomedicine

Science China Life Sciences

Volumn 55, Issue 10, 2012, Pages 843-861

  Tong, Sheng ^a   Cradick, Thomas J ^a   Ma, Yan ^b   Dai, ZhiFei ^b   Bao, Gang ^a,b  

^a Emory University   (United States)

^b PEKING UNIVERSITY   (China)

Author keywords

contrast agent; designer nuclease; drug delivery; imaging probe; nanomedicine

Indexed keywords

FLUORESCENT DYE;

COMPUTER ASSISTED TOMOGRAPHY; MOLECULAR IMAGING; NANOMEDICINE; NUCLEAR MAGNETIC RESONANCE IMAGING; REVIEW;

FLUORESCENT DYES; MAGNETIC RESONANCE IMAGING; MOLECULAR IMAGING; NANOMEDICINE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84868353843     PISSN: 16747305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11427-012-4380-1     Document Type: Review

References (180)

1. Wgner V, Dullaart A, Bock A K, et al. The emerging nanomedicine landscape. Nat Biotechnol, 2006, 24: 1211-1217.
2. Nie S M, Yun X, Gloria J K, et al. Nanotechnology Applications in Cancer. Ann Rev Biomed Eng, 2007, 9: 257-288.
3. Kim B Y, Rutka J T, Chan W C. Nanomedicine. N Engl J Med, 2010, 363: 2434-2443.
4. Smith A M, Gao X, Nie S. Quantum dot nanocrystals for in vivo molecular and cellular imaging. Photochem Photobiol, 2004, 80: 377-385.
5. Nitin N, Santangelo P J, Kim G, et al. Peptide-linked molecular beacons for efficient delivery and rapid mRNA detection in living cells. Nucleic Acids Res, 2004, 32: e58.
6. Nie S, Emory S R. Probing single molecules and single nanoparticles by surface-enhanced raman scattering. Science, 1997, 275: 1102-1106.
7. Chan W C, Nie S. Quantum dot bioconjugates for ultrasensitive nonisotopic detection. Science, 1998, 281: 2016-2018.
8. Emory S R, Haskins W E, Nie S. Direct observation of size-dependent optical enhancement in single metal nanoparticles. J Am Chem Soc, 1998, 120: 8009-8010.
9. Han M, Gao X, Su J Z, et al. Quantum-dot-tagged microbeads for multiplexed optical coding of biomolecules. Nat Biotechnol, 2001, 19: 631-635.
10. Chan W C, Maxwell D J, Gao X, et al. Luminescent quantum dots for multiplexed biological detection and imaging. Curr Opin Biotechnol, 2002, 13: 40-46.
11. Gao X, Chan W C, Nie S. Quantum-dot nanocrystals for ultrasensitive biological labeling and multicolor optical encoding. J Biomed Opt, 2002, 7: 532-537.
12. Bailey R E, Nie S. Alloyed semiconductor quantum dots: tuning the optical properties without changing the particle size. J Am Chem Soc, 2003, 125: 7100-7106.
13. Gao X, Cui Y, Levenson R M, et al. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol, 2004, 22: 969-976.
14. Lidke D S, Nagy P, Heintzmann R, et al. Quantum dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat Biotechnol, 2004, 22: 198-203.
15. Bruchez M, Moronne M, Gin P, et al. Semiconductor nanocrystals as fluorescent biological labels. Science, 1998, 281: 2013-2016.
16. Akerman M E, Chan W C, Laakkonen P, et al. Nanocrystal targeting in vivo. Proc Natl Acad Sci USA, 2002, 99: 12617-12621.
17. Dubertret B, Skourides P, Norris D J, et al. In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science, 2002, 298: 1759-1762.
18. Wu X, Liu H, Liu J, et al. Immunofluorescent labeling of cancer marker Her2 and other cellular targets with semiconductor quantum dots. Nat Biotechnol, 2003, 21: 41-46.
19. Jaiswal J K, Mattoussi H, Mauro J M, et al. Long-term multiple color imaging of live cells using quantum dot bioconjugates. Nat Biotechnol, 2003, 21: 47-51.
20. Larson D R, Zipfel W R, Williams R M, et al. Water-soluble quantum dots for multiphoton fluorescence imaging in vivo. Science, 2003, 300: 1434-1436.
21. Ishii D, Kinbara K, Ishida Y, et al. Chaperonin-mediated stabilization and ATP-triggered release of semiconductor nanoparticles. Nature, 2003, 423: 628-632.
22. Medintz I L, Clapp A R, Mattoussi H, et al. Self-assembled nanoscale biosensors based on quantum dot FRET donors. Nat Mater, 2003, 2: 630-638.
23. Dahan M, Levi S, Luccardini C, et al. Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking. Science, 2003, 302: 442-445.
24. Voura E B, Jaiswal J K, Mattoussi H, et al. Tracking metastatic tumor cell extravasation with quantum dot nanocrystals and fluorescence emission-scanning microscopy. Nat Med, 2004, 10: 993-998.
25. Garon E B, Marcu L, Luong Q, et al. Quantum dot labeling and tracking of human leukemic, bone marrow and cord blood cells. Leuk Res, 2007, 31: 643-651.
26. Hama Y, Koyama Y, Urano Y, et al. Simultaneous two-color spectral fluorescence lymphangiography with near infrared quantum dots to map two lymphatic flows from the breast and the upper extremity. Breast Cancer Res Treat, 2007, 103: 23-28.
27. Chattopadhyay P K, Price D A, Harper T F, et al. Quantum dot semiconductor nanocrystals for immunophenotyping by polychromatic flow cytometry. Nat Med, 2006, 12: 972-977.
28. Howarth M, Takao K, Hayashi Y, et al. Targeting quantum dots to surface proteins in living cells with biotin ligase. Proc Natl Acad Sci USA, 2005, 102: 7583-7588.
29. Bonasio R, Carman C V, Kim E, et al. Specific and covalent labeling of a membrane protein with organic fluorochromes and quantum dots. Proc Natl Acad Sci USA, 2007, 104: 14753-14758.
30. Chang E, Miller J S, Sun J, et al. Protease-activated quantum dot probes. Biochem Biophys Res Commun, 2005, 334: 1317-1321.
31. Xu C, Xing B, Rao J. A self-assembled quantum dot probe for detecting beta-lactamase activity. Biochem Biophys Res Commun, 2006, 344: 931-935.
32. Clapp A R, Medintz I L, Uyeda H T, et al. Quantum dot-based multiplexed fluorescence resonance energy transfer. J Am Chem Soc, 2005, 127: 18212-18221.
33. Yao H, Zhang Y, Xiao F, et al. Quantum dot/bioluminescence resonance energy transfer based highly sensitive detection of proteases. Angew Chem Int Ed, 2007, 46: 4346-4349.
34. Medintz I L, Clapp A R, Brunel F M, et al. Proteolytic activity monitored by fluorescence resonance energy transfer through quantum-dot-peptide conjugates. Nat Mater, 2006, 5: 581-589.
35. Goldman E R, Anderson G P, Tran P T, et al. Conjugation of luminescent quantum dots with antibodies using an engineered adaptor protein to provide new reagents for fluoroimmunoassays. Anal Chem, 2002, 74: 841-847.
36. Wang Y A, Li J J, Chen H, et al. Stabilization of inorganic nanocrystals by organic dendrons. J Am Chem Soc, 2002, 124: 2293-2298.
37. Chan W C W, Prendergast T L, Jain M, et al. One-step conjugation of biomolecules to luminescent nanocrystals. Proc SPIE, 2000, 3924: 2-9.
38. Pathak S, Choi S K, Arnheim N, et al. Hydroxylated quantum dots as luminescent probes for in situ hybridization. J Am Chem Soc, 2001, 123: 4103-4104.
39. Mirkin C A, Letsinger R L, Mucic R C, et al. A DNA-based method for rationally assembling nanoparticles into macroscopic materials. Nature, 1996, 382: 607-609.
40. Willard D M, Carillo L L, Jung J, et al. CdSe-ZnS quantum dots as resonance energy transfer donors in a model protein-protein binding assay. Nano Let, 2001, 1: 469-474.
41. Goldman E R, Balighian E D, Mattoussi H, et al. Avidin: a natural bridge for quantum dot-antibody conjugates. J Am Chem Soc, 2002, 124: 6378-6382.
42. Rosenthal S J, Tomlinson I, Adkins E M, et al. Targeting cell surface receptors with ligand-conjugated nanocrystals. J Am Chem Soc, 2002, 124: 4586-4594.
43. Dennis A M, Bao G. Quantum dot-fluorescent protein pairs as novel fluorescence resonance energy transfer probes. Nano Lett, 2008, 8: 1439-1445.
44. Sapsford K E, Pons T, Medintz I L, et al. Biosensing with luminescent semiconductor quantum dots. Sensors-Basel, 2006, 6: 925-953.
45. Qu L, Peng X. Control of photoluminescence properties of CdSe nanocrystals in growth. J Am Chem Soc, 2002, 124: 2049-2055.
46. Striolo A, Ward J, Prausnitz J M, et al. Molecular weight, osmotic second virial coefficient, and extinction coefficient of colloidal CdSe nanocrystals. J Phys Chem B, 2002, 106: 5500-5505.
47. Chan W C W, Maxwell D J, Gao X H, et al. Luminescent quantum dots for multiplexed biological detection and imaging. Curr Opin Biotech, 2002, 13: 40-46.
48. Lakowicz J R. Principles of fluorescence spectroscopy. New York: Springer, 2006.
49. Clapp A R, Medintz I L, Mattoussi H. Forster resonance energy transfer investigations using quantum-dot fluorophores. Chem Phys Chem, 2006, 7: 47-57.
50. Sapsford K E, Pons T, Medintz I L, et al. Kinetics of metal-affinity driven self-assembly between proteins or peptides and CdSe-ZnS quantum dots. J Phys Chem C, 2007, 111: 11528-11538.
51. Susumu K, Uyeda H T, Medintz I L, et al. Enhancing the stability and biological functionalities of quantum dots via compact multifunctional ligands. J Am Chem Soc, 2007, 129: 13987-13996.
52. Shaner N C, Campbell R E, Steinbach P A, et al. Improved monomeric red, orange and yellow fluorescent proteins derived from Discosoma sp. red fluorescent protein. Nat Biotechnol, 2004, 22: 1567-1572.
53. Shaner N C, Steinbach P A, Tsien R Y. A guide to choosing fluorescent proteins. Nat Methods, 2005, 2: 905-909.
54. Busa W B, Nuccitelli R. Metabolic regulation via intracellular pH. Am J Physiol, 1984, 246: R409-R438.
55. Tyagi S, Kramer F R. Molecular beacons: probes that fluoresce upon hybridization. Nat Biotechnol, 1996, 14: 303-308.
56. Tyagi S, Bratu D P, Kramer F R. Multicolor molecular beacons for allele discrimination. Nat Biotechnol, 1998, 16: 49-53.
57. Li J J, Geyer R, Tan W. Using molecular beacons as a sensitive fluorescence assay for enzymatic cleavage of single-stranded DNA. Nucleic Acids Res, 2000, 28: E52.
58. Dirks R W, Molenaar C, Tanke H J. Methods for visualizing RNA processing and transport pathways in living cells. Histochem Cell Biol, 2001, 115: 3-11.
59. Molenaar C, Marras S A, Slats J C, et al. Linear 2′ O-Methyl RNA probes for the visualization of RNA in living cells. Nucleic Acids Res, 2001, 29: E89-89.
60. Sokol D L, Zhang X, Lu P, et al. Real time detection of DNA. RNA hybridization in living cells. Proc Natl Acad Sci USA, 1998, 95: 11538-11543.
61. Vet J A, Majithia A R, Marras S A, et al. Multiplex detection of four pathogenic retroviruses using molecular beacons. Proc Natl Acad Sci USA, 1999, 96: 6394-6399.
62. Kostrikis L G, Tyagi S, Mhlanga M M, et al. Spectral genotyping of human alleles. Science, 1998, 279: 1228-1229.
63. Piatek A S, Tyagi S, Pol A C, et al. Molecular beacon sequence analysis for detecting drug resistance in Mycobacterium tuberculosis. Nat Biotech, 1998, 16: 359-363.
64. Bratu D P, Cha B J, Mhlanga M M, et al. Visualizing the distribution and transport of mRNAs in living cells. Proc Natl Acad Sci USA, 2003, 100: 13308-13313.
65. Tsourkas A, Behlke M A, Xu Y, et al. Spectroscopic features of dual fluorescence/luminescence resonance energy-transfer molecular beacons. Anal Chem, 2003, 75: 3697-3703.
66. Santangelo P J, Nix B, Tsourkas A, et al. Dual FRET molecular beacons for mRNA detection in living cells. Nucleic Acids Res, 2004, 32: e57.
67. Nitin N, Santangelo P J, Kim G, et al. Peptide-linked molecular beacons for efficient delivery and rapid mRNA detection in living cells. Nucleic Acids Res, 2004, 32: e58.
68. Tyagi S, Alsmadi O. Imaging native beta-actin mRNA in motile fibroblasts. Biophys J, 2004, 87: 4153-4162.
69. Peng X H, Cao Z H, Xia J T, et al. Real-time detection of gene expression in cancer cells using molecular beacon imaging: new strategies for cancer research. Cancer Res, 2005, 65: 1909-1917.
70. Medley C D, Drake T J, Tomasini J M, et al. Simultaneous monitoring of the expression of multiple genes inside of single breast carcinoma cells. Anal Chem, 2005, 77: 4713-4718.
71. Tsourkas A, Behlke M A, Bao G. Structure-function relationships of shared-stem and conventional molecular beacons. Nucleic Acids Res, 2002, 30: 4208-4215.
72. King F W, Liszewski W, Ritner C, et al. High-throughput tracking of pluripotent human embryonic stem cells with dual fluorescence resonance energy transfer molecular beacons. Stem Cells Dev, 2011, 20: 475-484.
73. Chen A K, Rhee W J, Bao G, et al. Delivery of molecular beacons for live-cell imaging and analysis of RNA. Methods Mol Biol, 2011, 714: 159-174.
74. Giles R V, Ruddell C J, Spiller D G, et al. Single base discrimination for ribonuclease H-dependent antisense effects within intact human leukaemia cells. Nucleic Acids Res, 1995, 23: 954-961.
75. Barry M A, Eastman A. Identification of deoxyribonuclease II as an endonuclease involved in apoptosis. Arch Biochem Biophys, 1993, 300: 440-450.
76. Giles R V, Spiller D G, Grzybowski J, et al. Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells. Nucleic Acids Res, 1998, 26: 1567-1575.
77. Walev I, Bhakdi S C, Hofmann F, et al. Delivery of proteins into living cells by reversible membrane permeabilization with streptolysin-O. Proc Natl Acad Sci USA, 2001, 98: 3185-3190.
78. Wadia J S, Dowdy S F. Transmembrane delivery of protein and peptide drugs by TAT-mediated transduction in the treatment of cancer. Adv Drug Deliv Rev, 2005, 57: 579-596.
79. Brooks H, Lebleu B, Vives E. Tat peptide-mediated cellular delivery: back to basics. Adv Drug Deliv Rev, 2005, 57: 559-577.
80. Nitin N, Bao G. NLS peptide conjugated molecular beacons for visualizing nuclear RNA in living cells. Bioconj Chem, 2008, 19: 2205-2211.
81. Czernin J, Allen-Auerbach M, Schelbert H. Improvements in cancer staging with PET/CT: literature-based evidence as of September 2006. J Nuclear Med, 2007, 48: 78S.
82. Judenhofer M S, Wehrl H F, Newport D F, et al. Simultaneous PET-MRI: a new approach for functional and morphological imaging. Nat Med, 2008, 14: 459-465.
83. Higuchi T, Anton M, Dumler K, et al. Combined reporter gene PET and iron oxide MRI for monitoring survival and localization of transplanted cells in the rat heart. J Nucl Med, 2009, 50: 1088-1094.
84. Xu H, Regino C A, Koyama Y, et al. Preparation and preliminary evaluation of a biotin-targeted, lectin-targeted dendrimer-based probe for dual-modality magnetic resonance and fluorescence imaging. Bioconjug Chem, 2007, 18: 1474-1482.
85. Koyama Y, Talanov V S, Bernardo M, et al. A dendrimer-based nanosized contrast agent dual-labeled for magnetic resonance and optical fluorescence imaging to localize the sentinel lymph node in mice. J Magn Reson Imaging, 2007, 25: 866-871.
86. Lee S K, Chen X. Dual-modality probes for in vivo molecular imaging. Mol Imaging, 2009, 8: 87-100.
87. Carmeliet P. Angiogenesis in health and disease. Nat Med, 2003, 9: 653-660.
88. Lee H Y, Li Z, Chen K, et al. PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med, 2008, 49: 1371-1379.
89. Xie J, Huang J, Li X, et al. Iron oxide nanoparticle platform for biomedical applications. Curr Med Chem, 2009, 16: 1278-1294.
90. Shokeen M, Fettig N M, Rossin R. Synthesis, in vitro and in vivo evaluation of radiolabeled nanoparticles. Q J Nucl Med Mol Imaging, 2008, 52: 267-277.
91. Wang Y X, Hussain S M, Krestin G P. Superparamagnetic iron oxide contrast agents: physicochemical characteristics and applications in MR imaging. Eur Radiol, 2001, 11: 2319-2331.
92. Bjornerud A, Wendland M F, Johansson L, et al. Use of intravascular contrast agents in MRI. Acad Radiol, 1998, 5: S223-225.
93. Weissleder R, Bogdanov A, Neuwelt E A, et al. Long-circulating iron-oxides for MR imaging. Adv Drug Deliv Rev, 1995, 16: 321-334.
94. Jun Y W, Huh Y M, Choi J S, et al. Nanoscale size effect of magnetic nanocrystals and their utilization for cancer diagnosis via magnetic resonance imaging. J Am Chem Soc, 2005, 127: 5732-5733.
95. Xu C J, Sun S H. Monodisperse magnetic nanoparticles for biomedical applications. Polymer Int, 2007, 56: 821-826.
96. Lee J H, Huh Y M, Jun Y W, et al. Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging. Nat Med, 2007, 13: 95-99.
97. Nitin N, LaConte L E, Zurkiya O, et al. Functionalization and peptide-based delivery of magnetic nanoparticles as an intracellular MRI contrast agent. J Biol Inorg Chem, 2004, 9: 706-712.
98. Yu W W, Chang E, Sayes C M, et al. Aqueous dispersion of monodisperse magnetic iron oxide nanocrystals through phase transfer. Nanotechnology, 2006, 17: 4483-4487.
99. Gossuin Y, Gillis P, Hocq A, et al. Magnetic resonance relaxation properties of superparamagnetic particles. Wiley Interdiscip Rev Nanomed Nanobiotechnol, 2009, 1: 299-310.
100. Nahrendorf M, Jaffer F A, Kelly K A, et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation, 2006, 114: 1504-1511.
101. Montet X, Montet-Abou K, Reynolds F, et al. Nanoparticle imaging of integrins on tumor cells. Neoplasia, 2006, 8: 214-222.
102. Winter P M, Morawski A M, Caruthers S D, et al. Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation, 2003, 108: 2270-2274.
103. 64Cu-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent. Bioconjug Chem, 2010, 21: 715-722.
104. Gillis P, Koenig S H. Transverse relaxation of solvent protons induced by magnetized spheres: application to ferritin, erythrocytes, and magnetite. Magn Reson Med, 1987, 5: 323-345.
105. 2-shortening by strongly magnetized spheres: a partial refocusing model. Magn Reson Med, 2002, 47: 257-263.
106. 2-shortening by weakly magnetized particles: the chemical exchange model. Magn Reson Med, 2001, 45: 1014-1020.
107. 2 NMRD profiles of solutions of magnetic nanoparticles. Magn Reson Med, 1995, 34: 227-233.
108. Jun Y W, Seo J W, Cheon A. Nanoscaling laws of magnetic nanoparticles and their applicabilities in biomedical sciences. Acc Chem Res, 2008, 41: 179-189.
109. Tromsdorf U I, Bigall N C, Kaul M G, et al. Size and surface effects on the MRI relaxivity of manganese ferrite nanoparticle contrast agents. Nano Letters, 2007, 7: 2422-2427.
110. Yu W W, Falkner J C, Yavuz C T, et al. Synthesis of monodisperse iron oxide nanocrystals by thermal decomposition of iron carboxylate salts. Chem Commun, 2004, 2306-2307.
111. Xie J, Peng S, Brower N, et al. One-pot synthesis of monodisperse iron oxide nanoparticles for potential biomedical applications. Pure Appl Chem, 2006, 78: 1003-1014.
112. Li J J, Wang Y A, Guo W Z, et al. Large-scale synthesis of nearly monodisperse CdSe/CdS core/shell nanocrystals using air-stable reagents via successive ion layer adsorption and reaction. J Am Chem Soc, 2003, 125: 12567-12575.
113. 4 nanoparticles for reduced non-specific uptake by macrophage cells. Adv Mater, 2007, 19: 3163-3166.
114. Torchilin V P, Trubetskoy V S. Which polymers can make nanoparticulate drug carriers long-circulating. Adv Drug Deliv Rev, 1995, 16: 141-155.
115. 2 relaxivity. Nano Lett, 2010, 10: 4607-4613.
116. Josephson L, Perez J M, Weissleder R. Magnetic nanosensors for the detection of oligonucleotide sequences. Angew Chem Int Edit, 2001, 40: 3204-3206.
117. Hazarika P, Ceyhan B, Niemeyer C M. Reversible switching of DNA-gold nanoparticle aggregation. Angew Chem Int Edit, 2004, 43: 6469-6471.
118. Montet X, Funovics M, Montet-Abou K, et al. Multivalent effects of RGD peptides obtained by nanoparticle display. J Med Chem, 2006, 49: 6087-6093.
119. Pellegrino T, Manna L, Kudera S, et al. Hydrophobic nanocrystals coated with an amphiphilic polymer shell: A general route to water soluble nanocrystals. Nano Lett, 2004, 4: 703-707.
120. Stolnik S, Illum L, Davis S S. Long circulating microparticulate drug carriers. Adv Drug Deliv Rev, 1995, 16: 195-214.
121. Liu Z, Davis C, Cai W, et al. Circulation and long-term fate of functionalized, biocompatible single-walled carbon nanotubes in mice probed by Raman spectroscopy. Proc Natl Acad Sci USA, 2008, 105: 1410-1415.
122. 64Cu-labeled magnetic nanoparticles as a dual-modality PET/MR imaging agent. Bioconjug Chem, 2010, 21: 715-722.
123. Torchilin V P. PEG-based micelles as carriers of contrast agents for different imaging modalities. Adv Drug Deliv Rev, 2002, 54: 235-252.
124. Johnsson M, Hansson P, Edwards K. Spherical micelles and other self-assembled structures in dilute aqueous mixtures of poly(ethylene glycol) lipids. J Phys Chem B, 2001, 105: 8420-8430.
125. Turro N J, Yekta A. Luminescent probes for detergent solutions-simple procedure for determination of mean aggregation number of micelles. J Am Chem Soc, 1978, 100: 5951-5952.
126. Tong S, Hou S, Ren B, et al. Self-assembly of phospholipid-PEG coating on nanoparticles through dual solvent exchange. Nano Lett, 2011, 11: 3720-3726.
127. Zhu M T, Wang B, Wang Y, et al. Endothelial dysfunction and inflammation induced by iron oxide nanoparticle exposure: Risk factors for early atherosclerosis. Toxicol Lett, 2011, 203: 162-171.
128. Hyafil F, Cornily J C, Feig J E, et al. Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med, 2007, 13: 636-641.
129. Haller C, Hizoh I. The cytotoxicity of iodinated radiocontrast agents on renal cells in vitro. Invest Radiol, 2004, 39: 149-154.
130. Kong W H, Lee W J, Cui Z Y, et al. Nanoparticulate carrier containing water-insoluble iodinated oil as a multifunctional contrast agent for computed tomography imaging. Biomaterials, 2007, 28: 5555-5561.
131. Badea C T, Athreya K K, Espinosa G, et al. Computed tomography imaging of primary lung cancer in mice using a liposomal-iodinated contrast agent. PLoS ONE, 2012, 7: e34496.
132. Hoglund P, Leander P, Hustvedt S O, et al. Human pharmacokinetics and modeling of the concentration-attenuation relationship of a new liposomal liver-specific contrast agent for CT. Acad Radiol, 1998, 5: S47-S48.
133. Kim D, Park S, Lee J H, et al. Antibiofouling polymer-coated gold nanoparticles as a contrast agent for in vivo x-ray computed tomography imaging. J Am Chem Soc, 2007, 129: 7661-7665.
134. Wang H, Zheng L F, Guo R, et al. Dendrimer-entrapped gold nanoparticles as potential CT contrast agents for blood pool imaging. Nanoscale Res Lett, 2012, 7: 190-197.
135. Liu H, Wang H, Guo R, et al. Size-controlled synthesis of dendrimer-stabilized silver nanoparticles for X-ray computed tomography imaging applications. Polym Chem-UK, 2010, 1: 1677-1683.
136. Rabin O, Perez J M, Grimm J, et al. An X-ray computed tomography imaging agent based on long-circulating bismuth sulphide nanoparticles. Nat Mater, 2006, 5: 118-122.
137. Ai K L, Liu Y L, Liu J H, et al. Large-scale synthesis of Bi2S3 nanodots as a contrast agent for in vivo X-ray computed tomography imaging. Adv Mater, 2011, 23: 4886-4891.
138. Kinsella J M, Jimenez R E, Karmali P P, et al. X-Ray computed tomography imaging of breast cancer by using targeted peptide-labeled bismuth sulfide nanoparticles. Angew Chem Int Edit, 2011, 50: 12308-12311.
139. Oh M H, Lee N, Kim H, et al. Large-scale synthesis of bioinert tantalum oxide nanoparticles for X-ray computed tomography imaging and bimodal image-guided sentinel lymph node mapping. J Am Chem Soc, 2011, 133: 5508-5515.
140. x core/shell nanoparticles for simultaneous magnetic resonance imaging and X-ray computed tomography. J Am Chem Soc, 2012, 134: 10309-10312.
141. Jain R K. Delivery of molecular and cellular medicine to solid tumors. Adv Drug Deliv Rev, 2001, 46: 149-168.
142. von Maltzahn G, Park J H, Lin K Y, et al. Nanoparticles that communicate in vivo to amplify tumour targeting. Nat Mater, 2011, 10: 545-552.
143. Weissleder R, Stark D D, Engelstad B L, et al. Superparamagnetic iron oxide: pharmacokinetics and toxicity. AJR Am J Roentgenol, 1989, 152: 167-173.
144. Namiki Y, Namiki T, Yoshida H, et al. A novel magnetic crystal-lipid nanostructure for magnetically guided in vivo gene delivery. Nat Nanotechnol, 2009, 4: 598-606.
145. Fortin J P, Wilhelm C, Servais J, et al. Size-sorted anionic iron oxide nanomagnets as colloidal mediators for magnetic hyperthermia. J Am Chem Soc, 2007, 129: 2628-2635.
146. Alexiou C, Arnold W, Klein R J, et al. Locoregional cancer treatment with magnetic drug targeting. Cancer Res, 2000, 60: 6641-6648.
147. Park J H, von Maltzahn G, Ruoslahti E, et al. Micellar hybrid nanoparticles for simultaneous magnetofluorescent imaging and drug delivery. Angew Chem Int Edit, 2008, 47: 7284-7288.
148. Jain T K, Richey J, Strand M, et al. Magnetic nanoparticles with dual functional properties: drug delivery and magnetic resonance imaging. Biomaterials, 2008, 29: 4012-4021.
149. Guthi J S, Yang S G, Huang G, et al. MRI-visible micellar nanomedicine for targeted drug delivery to lung cancer cells. Mol Pharm, 2010, 7: 32-40.
150. Liong M, Lu J, Kovochich M, et al. Multifunctional inorganic nanoparticles for imaging, targeting, and drug delivery. ACS Nano, 2008, 2: 889-896.
151. Dilnawaz F, Singh A, Mohanty C, et al. Dual drug loaded superparamagnetic iron oxide nanoparticles for targeted cancer therapy. Biomaterials, 2010, 31: 3694-3706.
152. Santra S, Kaittanis C, Grimm J, et al. Drug/dye-loaded, multifunctional iron oxide nanoparticles for combined targeted cancer therapy and dual optical/magnetic resonance imaging. Small, 2009, 5: 1862-1868.
153. Kim J, Kim H S, Lee N, et al. Multifunctional uniform nanoparticles composed of a magnetite nanocrystal core and a mesoporous silica shell for magnetic resonance and fluorescence imaging and for drug delivery. Angew Chem Int Ed Engl, 2008, 47: 8438-8441.
154. Nobuto H, Sugita T, Kubo T, et al. Evaluation of systemic chemotherapy with magnetic liposomal doxorubicin and a dipole external electromagnet. Int J Cancer, 2004, 109: 627-635.
155. Medarova Z, Pham W, Farrar C, et al. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med, 2007, 13: 372-377.
156. Lee J H, Lee K, Moon S H, et al. All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. Angew Chem Int Ed Engl, 2009, 48: 4174-4179.
157. Shin J M, Anisur R M, Ko M K, et al. Hollow manganese oxide nanoparticles as multifunctional agents for magnetic resonance imaging and drug delivery. Angew Chem Int Edit, 2009, 48: 321-324.
158. Choi J S, Lee J H, Shin T H, et al. Self-confirming "AND" logic nanoparticles for fault-free MRI. J Am Chem Soc, 2010, 132: 11015-11017.
159. Bartlett D W, Su H, Hildebrandt I J, et al. Impact of tumor-specific targeting on the biodistribution and efficacy of siRNA nanoparticles measured by multimodality in vivo imaging. Proc Natl Acad Sci USA, 2007, 104: 15549-15554.
160. Chen W, Xu N, Xu L, et al. Multifunctional magnetoplasmonic nanoparticle assemblies for cancer therapy and diagnostics (theranostics). Macromol Rapid Commun, 2010, 31: 228-236.
161. Hu J, Qian Y, Wang X, et al. Drug-loaded and superparamagnetic iron oxide nanoparticle surface-embedded amphiphilic block copolymer micelles for integrated chemotherapeutic drug delivery and MR imaging. Langmuir, 2012, 28: 2073-2082.
162. Kopelman R, Koo Y E L, Philbert M, et al. Multifunctional nanoparticle platforms for in vivo MRI enhancement and photodynamic therapy of a rat brain cancer. J Magn Magn Mater, 2005, 293: 404-410.
163. Zheng J, Allen C, Serra S, et al. Liposome contrast agent for CT-based detection and localization of neoplastic and inflammatory lesions in rabbits: validation with FDG-PET and histology. Contrast Media Mol Imag, 2010, 5: 147-154.
164. Barth B M, Sharma R, Altinoglu E I, et al. Bioconjugation of calcium phosphosilicate composite nanoparticles for selective targeting of human breast and pancreatic cancers in vivo. ACS Nano, 2010, 4: 1279-1287.
165. Guo R, Zhang L, Qian H, et al. Multifunctional nanocarriers for cell imaging, drug delivery, and near-IR photothermal therapy. Langmuir, 2010, 26: 5428-5434.
166. Lin X, Xie J, Niu G, et al. Chimeric ferritin nanocages for multiple function loading and multimodal imaging. Nano Lett, 2011, 11: 814-819.
167. Jain T K, Morales M A, Sahoo S K, et al. Iron oxide nanoparticles for sustained delivery of anticancer agents. Mol Pharm, 2005, 2: 194-205.
168. Dames P, Gleich B, Flemmer A, et al. Targeted delivery of magnetic aerosol droplets to the lung. Nat Nanotechnol, 2007, 2: 495-499.
169. Wood A J, Lo T W, Zeitler B, et al. Targeted genome editing across species using ZFNs and TALENs. Science, 2011, 333: 307.
170. Boch J, Scholze H, Schornack S, et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science, 2009, 326: 1509-1512.
171. Porteus M H, Baltimore D. Chimeric nucleases stimulate gene targeting in human cells. Science, 2003, 300: 763.
172. Rouet P, Smih F, Jasin M. Expression of a site-specific endonuclease stimulates homologous recombination in mammalian cells. Proc Natl Acad Sci USA, 1994, 91: 6064-6068.
173. Bitinaite J, Wah D A, Aggarwal A K, et al. Fok I dimerization is required for DNA cleavage. Proc Natl Acad Sci USA, 1998, 95: 10570-10575.
174. Smith J, Bibikova M, Whitby F G, et al. Requirements for double-strand cleavage by chimeric restriction enzymes with zinc finger DNA-recognition domains. Nucleic Acids Res, 2000, 28: 3361-3369.
175. Moscou M J, Bogdanove A J. A simple cipher governs DNA recognition by TAL effectors. Science, 2009, 326: 1501.
176. Cradick T J, Ambrosini G, Iseli C, et al. ZFN-site searches genomes for zinc finger nuclease target sites and off-target sites. BMC Bioinformatics, 2011, 12: 152.
177. Miller J C, Holmes M C, Wang J, et al. An improved zinc-finger nuclease architecture for highly specific genome editing. Nat Biotechnol, 2007, 25: 778-785.
178. Ramirez C L, Certo M T, Mussolino C, et al. Engineered zinc finger nickases induce homology-directed repair with reduced mutagenic effects. Nucleic Acids Res, 2012, 40: 5560-5568.
179. + T cells by genome editing using zinc-finger nucleases. Nat Biotechnol, 2008, 26: 808-816.
180. Platt O S, Brambilla D J, Rosse W F, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med, 1994, 330: 1639-1644.